Board and Management
Chair, Hugh Morgan AC, LLB, BCom: Hugh Morgan is Principal of First Charnock Pty Ltd. Hugh was appointed Chief Executive Officer of Western Mining Corporation (1990-2003) and prior to that served as an Executive Officer (1976-1986) and then Managing Director (from June 1986). Hugh has served as a Director of Alcoa of Australia Limited (1977-1998 and 2002-2003); Director of Alcoa Inc. (1998-2001); Member of the Board of the Reserve Bank of Australia (1981-1984 and 1996-2007); President of the Australian Japan Business Co-Operation Committee (1999-2006); Joint Chair of the Commonwealth Business Council (2003-2005) and now Emeritus Director; President of the Business Council of Australia (2003-2005) and now an Honorary Member; Member of the Anglo American plc Australian Advisory Board (2006-2014). Hugh was a Member of the Lafarge International Advisory Board; is Chairman of the Order of Australia Association Foundation Limited; Trustee Emeritus of The Asia Society New York; Chairman Emeritus of the Asia Society AustralAsia Centre; Member of the Asia Society Australia Advisory Council; President of the National Gallery of Victoria Foundation. Hugh is a graduate in Law and Commerce from the University of Melbourne. Hugh has chaired BioDiem Ltd since 2007, and Opal since its formation.
Managing Director: Julie Phillips, BPharm, MSc, MBA, MPS, MAICD: Ms Julie Phillips is a pharmacist has a strong background in the biotech and pharmaceutical industry, having worked as the CEO and Director of start-up Australian biotechnology companies operating in the life sciences sector. She identified and inlicenced the oncolytic virus technology which was sold to Merck for $502m. As CEO of Biodiem Ltd she negotiated the LAIV licence to the World Health Organisation, and licences to the Serum Institute of India and Changchun BCHT Biotechnology Ltd; and many Australian and international research agreements including with the US Centers of Disease Control and Prevention (CDC). Julie is CEO fo BioDiem Ltd (a royalty-receiving company) and Managing Director of Opal. She is Chairman of Industry Innovation and Science Australia’s R&D Incentives Committee, until Feb 2020 was Chairman of AusBiotech Ltd, the peak biotechnology industry association in Australia, and is currently a non-executive director of the Medtech and Pharma Growth Centre, MTP Connect. Julie sits on the University of Newcastle’s Council, the Health Innovation Advisory Committee of the NH&MRC, the South Australian Premier’s Scientific Advisory Committee and the steering committee of the Australian Antimicrobial Resistance Network.
Non-executive Director: Ken Windle, BPharm, DipEc, MPS: Ken has a successful career in the Australian and international pharmaceutical industry and more recently with smaller Australian companies. Ken Windle worked 30 years with Glaxo/Glaxo Wellcome (now gsk) in International positions including Member of the Group’s Executive Committee. This career included Head of Global Commercialisation based in London, CEO of subsidiaries in UK, Australia, and Regional President Asia Pacific. He was Chairman and CEO of Advent Pharmaceuticals Pty Ltd which he co-founded in 2001 and sold in 2018. He was Director of Aus Bio Ltd, Chairman of their R&D Committee, Deputy Chair of Acrux, and NED of NZ Pharmaceuticals. He is Chairman of RMIT’s PAC and NED of Opal. He served 8 years as a Member of Innovation Australia which included Chairman of the Board’s COMET and P3 Committees, member of IIIF Committee, and PISG Working Group. He was Chairman of the working group in Victorian Governmentt’s Biotechnology Strategic Development Plan. Graduating from Otago University in Pharmacy and pharmacology, he further studied Economics at Massey University, and completed the Executive Programme at London Business School. Mr Windle has previously served as Consultant to the (Australian) Prime Minister’s Science Council on Industry Development, Director of the (Singapore) Economic Development Board EDB, and Singapore’s Committee on Competitiveness. He was for 2 three year terms Chairman of the APMA (now Medicines Australia), a member of the Pharmaceuticals Industry Advisory Committee, a member of Pharmaceuticals Industry Action Agenda (PIAAG), member of the Pharmaceuticals Industry Strategy Group (PISG), and has been twice a winner of the Governor of Victoria’s Export Prize.
Non-executive Director: Peter Snowball: Peter’s successful career in the financial markets started at Barclays Bank and then the London Futures Exchange. After emigrating to Australia in 1971 he traded on the Sydney Wool Futures Exchange for global clients. Then back in London for a short time Peter became a senior broker at Shearson Lehmann Brothers with his own client base of professional traders, trading mainly financial futures in Chicago. Later in Australia Peter set up a financial futures broking desk at Merrill Lynch in Sydney and subsequently at FIMAT Australia, broking interest rate futures into Singapore and Chicago. Peter moved to J B Were in 1994 where he switched to broking equities for retail clients and within five years became one of the biggest business writers in the Sydney office and in the Company. After a short time supporting the Philanthropic Services team, Peter left J B Were in 2014 and moved to roles with smaller private companies assisting in company turn-arounds and corporate transactions. Peter was the chairman of Philip Shaw Wines Pty Ltd until December 2019.
Company secretary: Melanie Leydin: Melanie Leydin holds a Bachelor of Business majoring in Accounting and CorporateLaw. She is a member of the Institute of Chartered Accountants, Fellow of the Governance Institute of Australia and is a Registered Company Auditor. She graduated February 2000 has been the principal of Leydin Freyer. The practice provides outsourced company secretarial and accounting services to public and private companies across a host of industries including but not limited to the Resources, technology, bioscience, biotechnology and health sectors. Melanie has over 25 years’ experience in the accounting profession and over 15 years as a company secretary. She has extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of companies and shareholder relations.